POLR3G Antibody

What is POLR3G and how does it differ from POLR3GL?

Basic Research Question

POLR3G (RNA polymerase III subunit G) is a specific peripheric component of RNA polymerase III that synthesizes small non-coding RNAs including 5S rRNA, snRNAs, tRNAs, and miRNAs from at least 500 distinct genomic loci . POLR3G and its paralog POLR3GL create two alternate forms of Pol III:

These two subunits create distinct Pol III isoforms with partially overlapping functions. Research shows that POLR3G is highly expressed during early development and subsequently attenuated during differentiation , whereas POLR3GL maintains more consistent expression in differentiated tissues. These isoforms lie in separate complexes, as demonstrated by co-immunoprecipitation studies showing that antibodies specific for either POLR3G or POLR3GL co-immunoprecipitated POLR3C but not the other POLR3G subunit .

How can researchers validate POLR3G antibody specificity?

Basic Research Question

Validating antibody specificity is crucial for reliable POLR3G research. A methodological approach includes:

• Western blot validation: Compare signals from samples with known POLR3G expression levels. Commercial POLR3G antibodies show predicted molecular weight between 26-30 kDa . Antibodies like Proteintech's 24701-1-AP have been validated in HeLa and K-562 cells .

• Positive and negative controls: Use cell lines with known high POLR3G expression (embryonic stem cells, cancer cell lines) versus those with lower expression (differentiated cells) .

• Cross-reactivity testing: Ensure the antibody doesn't detect POLR3GL. As noted in research by Haurie et al., polyclonal antibodies may cross-react with additional proteins in immunoblots of whole-cell extracts .

• Knockout validation: The most definitive method is testing in POLR3G knockout systems. As reported in the search results: "Although these polyclonal antibodies cross-reacted with additional proteins in immunoblots of whole-cell extracts, they successfully distinguished the two proteins in ESC lines overexpressing the mouse POLR3G or POLR3GL proteins" .

• Immunoprecipitation validation: Verify that the antibody can specifically immunoprecipitate its cognate Pol III subunit .

What are the recommended ChIP-seq protocols for studying POLR3G chromatin occupancy?

Advanced Research Question

ChIP-seq for POLR3G requires careful optimization due to potential challenges with antibody sensitivity and specificity. Based on published research methodologies:

• Antibody selection: Research shows variability in antibody performance for Pol III subunits. Van Bortle et al. built a genomic map by "mapping nearly half of the subunits of Pol III in an experimental approach known as chromatin immunoprecipitation (ChIP), which uses antibodies to pull down specific proteins" . Consider using antibodies against multiple Pol III subunits for validation.

• Sensitivity considerations: Studies indicate POLR3C antibodies often show greater sensitivity than POLR3G or POLR3GL antibodies. As noted: "Among these antibodies, the POLR3C antibody displayed the greatest specificity and sensitivity in ChIP-seq experiments. Therefore, we always observed more POLR3C-binding sites than POLR3G- or POLR3GL-binding sites" .

• Data analysis approach: For multicopy genes like tRNAs, standard RNA-seq mapping can be problematic. As Van Bortle notes: "The approach of ChIP, which pulls down large DNA fragments, helps us map and focus on genes that are actually expressed when we might otherwise mismap RNA reads to genes that are not active" .

• Comparative occupancy analysis: When studying both POLR3G and POLR3GL, use rank normalization of signal intensity across genes to accurately compare their binding patterns . Research shows "strong level of overlap in rank normalized signal intensity across genes of all promoter architectures" .

• Control recommendations: Include input DNA controls and, ideally, ChIP with antibodies against core Pol III subunits like POLR3D for comparison .

How does POLR3G expression change during cellular differentiation and development?

Intermediate Research Question

POLR3G shows dynamic expression changes during development and differentiation that can be methodologically studied:

• Developmental regulation: In mouse embryonic development, POLR3G is highly expressed in early stages and downregulated during differentiation. Research shows: "Downregulation of POLR3G is observed on differentiation of hESC and hiPSC, suggesting that POLR3G can be used as a molecular marker to readily identify undifferentiated pluripotent stem cells from their differentiated derivatives" .

• Methodological approaches for tracking changes:

  • Western blotting with quantitative standards: Comparing "immunoblot signals obtained using whole-cell extracts prepared from the same number of E14TG2a ESCs and primary MEFs to the signals given by increasing amounts of highly purified FLAG-tagged POLR3G and POLR3GL" .

  • ChIP-seq across differentiation stages: Studies found "a total of 223 genes were commonly targeted by POLR3G in both ESCs and MEFs, while only 20 and 41 genes were specifically bound, respectively, in these cell types" .

• Compensation mechanisms: When one paralog is depleted, the other may increase expression. For example, in POLR3GL knockout mice, researchers observed that "POLR3G levels were significantly increased in all three mutant mice. This again suggests partial compensatory effects via the up-regulation of the other Pol III isoform in these tissues" .

• Functional consequences: Research using inducible shRNA systems showed "decreased levels of POLR3G result in loss of pluripotency and promote differentiation of hESC to all three germ layers but have no effect on cell apoptosis" .

How can POLR3G and POLR3GL be distinguished experimentally despite their sequence similarity?

Advanced Research Question

Distinguishing between these paralogs requires specific technical approaches:

• Antibody-based discrimination: Generate and validate paralog-specific antibodies targeting divergent regions. Researchers have successfully raised "polyclonal antibodies against the first 146 residues of POLR3G and the first 151 residues of POLR3GL, respectively" .

• Immunoprecipitation followed by mass spectrometry: This approach can definitively identify which paralog is present in a complex. Studies found that "antibodies specific for either POLR3G or POLR3GL coimmunoprecipitated POLR3C but not the other POLR3G subunit, indicating that POLR3G and POLR3GL lie in separate complexes" .

• High-resolution separation techniques: "Fractionated a HeLa whole-cell extract by gel filtration chromatography and analyzed the resulting fractions by Western blot with antibodies against POLR3A and POLR3C" . This revealed distinct elution profiles.

• Paralog-specific PCR primers: Design primers targeting unique sequences for accurate transcript quantification.

• Epitope tagging strategies: Creating tagged versions allows unambiguous identification. Researchers established "stable mouse E14TG2a cell lines expressing either FLAG-AviTag–tagged POLR3G or POLR3GL using a lentiviral-based delivery method" .

What are the functional consequences of POLR3G knockout in different experimental models?

Advanced Research Question

POLR3G knockout yields varied phenotypes depending on the biological context, which researchers have studied using multiple methodologies:

How can researchers analyze POLR3G genomic binding patterns and target specificity?

Advanced Research Question

Analyzing POLR3G genomic binding requires specialized methodological approaches:

• Integrated genomic mapping: Multiple groups have established methodologies for comprehensive binding analysis:

  • "We identified target genes of POLR3G- and POLR3GL-containing Pol III complexes in mouse E14TG2a ESCs and MEFs using genome-wide ChIP-seq with antibodies raised against POLR3C, POLR3G, POLR3GL, and Pol II (RBP1)" .

  • For comparative analysis, using a multi-subunit approach provides validation: "Rank normalization of Pol III and transcription factor signal intensities illustrate this relationship, with high occupancy genes featuring strong signals for all subunits" .

• Target gene classification: Research shows POLR3G binds to various classes of Pol III genes:

  • Most binding sites map to "known Pol III target genes that include tRNA genes, 5S RNA genes, 7SK RNA genes, U6 small nuclear RNA genes, RNase MRP, Y RNA genes, vault RNA genes, and SINEs" .

  • Analyze binding patterns by gene class to identify any preference.

• Cell-type specific binding: Studies show both common and cell-specific targets:

  • "A total of 223 genes were commonly targeted by POLR3G in both ESCs and MEFs, while only 20 and 41 genes were specifically bound, respectively, in these cell types" .

  • Research indicates cell-specific binding may reflect "cell-type–specific expression of tRNA genes" .

• Correlation with chromatin features: "Individual Pol III subunit occupancies significantly correlate across all comparison groups, as well as with measures of chromatin accessibility, suggesting that ATAC-seq experiments can provide a general prediction of Pol III-transcribed gene activity" .

What is the relationship between POLR3G expression and cancer?

Advanced Research Question

POLR3G shows important associations with cancer that researchers have investigated through several methodological approaches:

• Cancer-specific expression: POLR3G shows elevated expression in specific cancer types:

  • "POLR3G is specifically overexpressed in clinical samples of triple-negative breast cancer (TNBC) but not in other molecular subtypes of breast cancer" .

  • Several studies have identified POLR3G as "the only component of the Pol III transcription apparatus that is significantly overexpressed in triple-negative breast cancer (TNBC) but not in other types of breast cancer" .

• Functional studies through genetic manipulation:

  • "CRISPR/Cas9-mediated suppression of POLR3G in the MDA-MB231 TNBC cell line decreases colony formation in soft agar assays and invasive growth in vitro" .

  • "The POLR3G KO impairs tumor growth and metastasis of intraductal xenografts in mice" .

• Molecular mechanisms: Research has uncovered specific downstream effects:

  • "Suppression of POLR3G activates the expression of FOXA1 and androgen receptor, two key factors that are characteristic of luminal and molecular apocrine breast cancers" .

  • MYC oncogene has been identified as an upstream regulator: "MYC promotes POLR3G gene expression, shaping Pol III identity and downstream transcription activities associated with cell proliferation" .

• Transcriptional impacts: POLR3G affects specific non-coding RNA transcription in cancer cells:

  • "POLR3G/RPC7alpha modulates Pol III transcriptome by specifically enhancing the transcription of snaR-A non-coding RNAs" .

How can I design experiments to determine if POLR3G and POLR3GL have redundant or distinct functions?

Advanced Research Question

Experimental designs to address the functional redundancy question include:

What are the recommended experimental controls when studying POLR3G in pluripotent stem cells?

Intermediate Research Question

When studying POLR3G in pluripotent stem cells, several methodological controls are essential:

• Pluripotency state verification: Monitor established pluripotency markers to ensure consistent cell state:

  • Research established that "neither POLR3G nor POLR3GL overexpression altered stem cell morphology or messenger RNA (mRNA) levels of the pluripotency marker" .

  • Include OCT4, SOX2, and NANOG assessment as these "serve as key regulators in the maintenance of hESC" .

• Differentiation controls: Include differentiated derivatives as negative controls:

  • "Downregulation of POLR3G is observed on differentiation of hESC and hiPSC, suggesting that POLR3G can be used as a molecular marker to readily identify undifferentiated pluripotent stem cells from their differentiated derivatives" .

• Paralog expression assessment: Quantify both POLR3G and POLR3GL levels:

  • Studies measured "the absolute protein expression levels in different cell lines" by comparing "the immunoblot signals obtained using whole-cell extracts prepared from the same number of E14TG2a ESCs and primary MEFs to the signals given by increasing amounts of highly purified FLAG-tagged POLR3G and POLR3GL" .

• Regulatory pathway controls: Include assessment of known upstream regulators:

  • Experimental results show "POLR3G is a downstream target of OCT4 and NANOG" and "POLR3G expression can be readily regulated by the Erk1/2 signaling pathway" .

• Functional readouts: Include multiple functional assays beyond expression measurement:

  • Studies found "decreased levels of POLR3G result in loss of pluripotency and promote differentiation of hESC to all three germ layers but have no effect on cell apoptosis" .

  • Conversely, "hESC expressing elevated levels of POLR3G are more resistant to differentiation" .